Grace Therapeutics
GRCE
8 hedge funds and large institutions have $784K invested in Grace Therapeutics in 2016 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
14% less capital invested
Capital invested by funds: $914K → $784K (-$130K)
33% less funds holding
Funds holding: 12 → 8 (-4)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$747 |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$612 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$37.8K |
| 2 |
Jane Street
New York
|
-$16K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$340 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
1
Perceptive Advisors
New York
| $336K | – | – | – |
|
|
2
Bank of Montreal
Toronto,
Ontario, Canada
| $245K | -$37.8K | -557 | -13% |
|
|
IIM
3
Intact Investment Management
Montreal,
Quebec, Canada
| $157K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $43K | +$747 | +11 | +2% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $1K | -$340 | -5 | -38% |
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
7
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $1K | +$612 | +9 | +225% |
|
|
8
Jane Street
New York
| – | -$16K | -215 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$5K | -75 | Closed |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$1K | -8 | Closed |
|
GRCE Hedge Fund Activity: Q2 2016 in Review
8 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q2 2016, worth a combined $784K — down 14% from $914K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GRCE and 0 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $747. The largest seller was Bank of Montreal, cutting an estimated $37.8K.
- 8 institutional investors held Grace Therapeutics (GRCE) as of Q2 2016, down from 12 in Q1 2016.
- Funds reported $784K of Grace Therapeutics stock for Q2 2016, down 14% quarter-over-quarter.
- 0 funds opened new Grace Therapeutics positions in Q2 2016 and 4 closed out, a net change of -4 holders.
- The largest Grace Therapeutics buyer in Q2 2016 was Renaissance Technologies, an estimated $747 added.
- The largest Grace Therapeutics seller in Q2 2016 was Bank of Montreal, an estimated $37.8K sold.
Based on aggregated 13F filings for Q2 2016.